Sir,

Chitnis *et al*[@ref1] have done an excellent job of determining the MIC of daptomycin, linezolid and teicoplanin in *S.aureus* and *Enterococcus faecalis* but they did not interpret the sensitivity results properly, as given below:

*(i)* Oxacillin disc diffusion (DD) has a sensitivity of only 91 per cent and specificity of only 58.9 per cent while cefoxitin DD has sensitivity and specificity of 97.8 & 100 per cent, respectively[@ref2]. Therefore, oxacillin DD could not have given a result identical to cefoxitin DD.

*(ii)* Though the authors have reported the susceptibility of erythromycin and clindamycin, but they did not make an effort to detect inducible resistance to clindamycin which has got immense clinical significance.

*(iii)* The table shows that resistance to ampicillin was 67.67 per cent while MRSA rate was 73.33 per cent which implies that almost 5 per cent of the MRSA isolates were actually sensitive to ampicillin[@ref1]. The authors seem to have committed an error in susceptibility test reporting.

*(iv)* For MRSA there is no need to test and report beta-lactams (Table) as these all are considered resistant irrespective of their zone diameters.

*(v)* CLSI has done away with vancomycin DD and recommends only MIC testing[@ref3]. Therefore, the data presented in Table on vancomycin susceptibility based on DD are not valid.

*(vi)* High level aminoglycoside (gentamicin 120 µg) needs to be tested for enterococci to determine its synergy with ampicillin/penicillin/vancomycin. The authors have tested 10 µg instead[@ref3].

*(vii)* According to CLSI (2009) the vancomycin MIC for susceptible is ≤ 2 µg/ml, intermediate is 4-8 µg/ml and resistant is ≥ 16 µg/ml. The authors have reported 16 MRSA isolates with MIC of 3µg/ml and classified these as sensitive[@ref3].
